| Literature DB >> 29286606 |
Shahrzad Ahmadi1, Hossein Goudarzi, Ahmad Jalilvand, Abdolreza Esmaeilzadeh.
Abstract
Objective: Cervical cancer is one of the most common cancers among women all over the world, and main cause is persistent infection with high risk human papillomavirus (HPV) strains. It has been reported that the distribution and prevalence of HPV types varies by geographical region, so that this is important for prevention by type-specific vaccines. The aim of current study was to determine the genotype distribution of HPV using the INNO-LiPA genotyping assay in Zanjan province, North West Iran.Entities:
Keywords: Human papilloma virus; INNO; LiPA; cervical cancer; Zanjan; Iran
Mesh:
Substances:
Year: 2017 PMID: 29286606 PMCID: PMC5980897 DOI: 10.22034/APJCP.2017.18.12.3373
Source DB: PubMed Journal: Asian Pac J Cancer Prev ISSN: 1513-7368
Primers and PCR Product Characteristics
| Gene | Primers | Product Size (bp) | Reference |
|---|---|---|---|
| L1 (HPV) | GP5+ TTTGTTACTGTGGTAGATACTAC | 150 | (Shikova et al., 2009) |
| GP6+ GAAAAATAAACTGTAAATCATATTC |
Figure 1PCR Analysis of DNA Samples Extracted Paraffin Embedded Tissues Using HPV GP5+ GP6+primers: lane 1, DNA Size marker; lane 2-11, HPV positive samples; lane 12, positive control; lane 13, negative control
HPV Genotypes Prevalence Based on Cytological Diagnosis
| HPV Types | Sample number | Age | Mono infection N=18 | Multiple infection | Multiple infection | Unknown types | pathological diagnosis | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N=50 | Mean age of positive samples | N=18 | Double infection | Triple infection | N=14 | LSIL | HSIL | SCC | |||
| N=8 | N=10 | N=32 | N=16 | N=2 | |||||||
| High risk | 18 | 24 | 46 | 10(55.5%) | 14(77.7%) | 4 (50%) | 10 (100%) | ------ | 18 (56.2%) | 6 (37.5%) | 0 (0) |
| 16 | 4 | 48.8 | 2 (11.1%) | 2 (11.1%) | 2 (25%) | 0 (0) | ------ | 0 (0) | 2 (12.5%) | 2 (100%) | |
| 31 | 4 | 54.3 | 2 (11.1%) | 2 (11.1%) | 0 (0) | 2 (20%) | ------ | 4 (12.5%) | 0 (0) | 0 (0) | |
| 51 | 5 | 43.6 | 2 (11.1%) | 3 (16.6%) | 1 (12.5%) | 2 (20%) | ------ | 2 (6.25%) | 3 (18.75%) | 0 (0) | |
| 56 | 2 | 36 | 0 (0) | 2 (11.1%) | 0 (0%) | 2 (20%) | ------ | 0 (0) | 2 (12.5%) | 0 (0) | |
| 73 | 8 | 42.1 | 2 (11.1%) | 6 (33.3%) | 0 (0) | 6 (60%) | ------ | 4 (12.5%) | 4 (25%) | 0 (0) | |
| Low risk | 6 | 13 | 44.8 | 0 (0) | 13 (72.2%) | 7 (87.5%) | 6 (60%) | ------ | 7 (21.8%) | 6(37.5%) | 0 (0) |
| 44 | 2 | 40.2 | 0 (0) | 2 (11.1%) | 0 (0) | 2 (20%) | ------ | 2 (6.25%) | 0 (0) | 0 (0) |
Figure 2HPV Genotyping Result Using INNO-LiPA Technique, line 1, Marker line; line 2, Conjugate control; line 3, hDNA control; line4, HPV control1; line5, HPV control 2; Right Strip, HPV18,6,73 genotypes; Left Strip, HPV18 genotype
Figure 3HPV Types Prevalence Based on Pathological Diagnosis